Core Viewpoint - Lidman has shown a significant stock price increase of 57.14% year-to-date, indicating strong market performance despite recent fluctuations [2]. Financial Performance - As of September 30, Lidman reported a revenue of 1.60 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 14.80%. The net profit attributable to shareholders was -4.25 million yuan, a decline of 800.43% compared to the previous year [3]. - The company has distributed a total of 1.43 billion yuan in dividends since its A-share listing, with 5.44 million yuan distributed over the last three years [4]. Stock Market Activity - On October 21, Lidman's stock price rose by 2.12%, reaching 7.70 yuan per share, with a trading volume of 87.37 million yuan and a turnover rate of 2.12%. The total market capitalization stood at 4.189 billion yuan [1]. - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) four times this year, with the most recent appearance on August 8 [3]. Shareholder Information - As of September 30, the number of shareholders for Lidman was 32,900, a decrease of 1.79% from the previous period. The average number of circulating shares per shareholder increased by 1.82% to 16,487 shares [3]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 424,900 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 2.2007 million shares [4]. Business Overview - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials. The revenue composition is as follows: 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, 13.21% from other services (such as property management), and 4.78% from biochemical raw materials [3]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors, with involvement in gene sequencing, assisted reproduction, and precision medicine [3].

证券代码：300289 证券简称：利德曼 公告编号：2025-042 北京利德曼生化股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2025 年 3 月 4 日召开第六届董事会第二次会议和第六届监事会第二次会议，审议通过 了《关于使用闲置自有资金进行委托理财的议案》，同意公司及子公司 使用额度不超过人民币70,000万元的暂时闲置自有资金进行委托理财， 用于购买银行、证券公司、信托公司、基金管理公司等金融机构发行的 安全性高、流动性好、中低风险的现金管理类产品或理财产品等，上述 额度自公司董事会审议通过之日起 12 个月内可循环滚动使用。内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于使用闲置自 有资金进行委托理财的公告》（公告编号：2025-007）、《关于使用闲置 自有资金进行委托理财的进展公告》（公告编号：2025-027、2025-028、 2025-031）。 一、公司及子公司使用闲置自有资金进行委托理财进展情况 公 ...

Core Viewpoint - Lidman has shown a significant stock price increase of 54.29% year-to-date, with recent fluctuations indicating a mixed performance in the short term [2]. Group 1: Stock Performance - As of October 15, Lidman’s stock price rose by 2.02% to 7.56 CNY per share, with a total market capitalization of 4.113 billion CNY [1]. - The stock has experienced a slight increase of 0.13% over the last five trading days, a decline of 4.91% over the last 20 days, and a substantial increase of 40.78% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Lidman reported a revenue of 160 million CNY, reflecting a year-on-year decrease of 14.80%, and a net profit attributable to shareholders of -4.2452 million CNY, a significant decline of 800.43% [3]. - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.4401 million CNY distributed over the last three years [4]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Lidman was 32,900, a decrease of 1.79% from the previous period, while the average circulating shares per person increased by 1.82% to 16,487 shares [3]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 424,900 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 2,200,700 shares [4]. Group 4: Business Overview - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with the majority of revenue (67.84%) coming from in vitro diagnostic reagents [3]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors, and is involved in various concept sectors including gene sequencing and cold chain logistics [3].

Core Viewpoint - Lidman has experienced a significant stock price increase of 55.31% year-to-date, despite a slight decline in recent trading days [2] Group 1: Stock Performance - As of October 10, Lidman’s stock price rose by 2.01% to 7.61 CNY per share, with a total market capitalization of 4.14 billion CNY [1] - The stock has seen a 0.13% decrease over the last five trading days and a 3.79% decrease over the last 20 days, while it has increased by 41.19% over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Lidman reported a revenue of 160 million CNY, representing a year-on-year decrease of 14.80%, and a net profit of -4.25 million CNY, a decline of 800.43% year-on-year [2] - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.44 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of September 19, the number of shareholders for Lidman was 33,500, a decrease of 4.99% from the previous period, with an average of 16,192 circulating shares per shareholder, an increase of 5.26% [2] - The top ten circulating shareholders include Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund, which increased its holdings by 424,900 shares, and Hua Xia Zhong Zheng 500 Index Enhanced A, which is a new shareholder with 2.20 million shares [3]

Core Points - The company, Lideman, announced plans to acquire up to 70% of the shares held by certain shareholders of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. in a cash transaction [1] - Prior to this transaction, the company did not hold any shares in the target company; post-transaction, the target company will become a subsidiary controlled by Lideman [1] - The transaction is expected to constitute a major asset restructuring as defined by the regulations governing listed companies [1] Transaction Details - The company is currently advancing the specific matters related to the major asset restructuring, including conducting due diligence, auditing, and valuation of the target company [1] - Communication and negotiation with relevant parties regarding the major asset restructuring are ongoing, and no formal transaction documents have been signed yet [1] - The company will adhere to legal and regulatory requirements for decision-making and information disclosure as the transaction progresses [1]

证券代码：300289 证券简称：利德曼 公告编号：2025-041 北京利德曼生化股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、本次交易尚处于筹划阶段，相关尽职调查、审计、评估等各项 工作尚未最终完成，交易相关方尚未签署正式协议，交易方案、交易 价格等核心要素仍需进一步协商；交易相关方尚需分别履行必要的内 外部决策、审批程序，存在未能通过有关决策、审批程序的风险。 2、本次交易存在不确定性，可能出现因外部环境变化导致交易条 件发生变化或公司与交易对方未能就交易方案达成一致等情形，进而 导致终止交易的风险，敬请广大投资者注意投资风险。 一、本次重大资产重组的基本情况 北京利德曼生化股份有限公司（以下简称"公司"或"上市公 司"）正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限 公司（以下简称"目标公司"）部分股东持有的目标公司合计不超过 70%的股份（以下简称"本次交易"）。本次交易前，公司未持有目标 公司的股份；本次交易完成后，公司将取得目标公司控制权，目标公 司将成为公司的控股子公司。 根据初步测算 ...

关于非独立董事辞职的公告 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")董事会于2025年9 月 24 日收到非独立董事郑允新先生递交的书面辞职报告。郑允新先生 因工作变动原因申请辞去公司董事职务，同时一并辞去公司董事会审计 委员会委员和提名委员会委员等职务。辞职后，郑允新先生将不在公司 担任任何职务。 郑允新先生上述职务原定任期至公司第六届董事会届满之日止。截 至本公告披露之日，郑允新先生未持有公司股份，亦不存在应当履行而 未履行的公开承诺。 根据《公司法》和《公司章程》等相关规定，郑允新先生的辞职不 会导致公司董事会人数低于法定人数，不会影响公司董事会正常运作， 其辞职报告自送达公司董事会之日起生效。公司将按照法定程序尽快完 成董事补选等相关后续工作。 证券代码：300289 证券简称：利德曼 公告编号：2025-040 郑允新先生在担任公司董事期间恪尽职守、勤勉尽责，在公司治理、 规范运作等方面发挥了重要作用，公司对郑允新先生在任职期间为公司 发展所做出的贡献表示衷心感谢！ 北京利德曼生化股份有 ...

Core Viewpoint - As of September 19, 2025, the number of shareholders for Lide Man (300289) is reported to be 33,544 [1] Company Summary - Lide Man has engaged with investors through an interactive platform, providing updates on shareholder numbers [1] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [1]

Core Viewpoint - Lidman has experienced a significant stock price increase of 56.73% year-to-date, but has recently faced declines in the short term, with a 4.60% drop over the last five trading days and a 16.52% drop over the last twenty days [2] Company Overview - Beijing Lidman Biochemical Co., Ltd. was established on November 5, 1997, and went public on February 16, 2012. The company is located in Beijing Economic and Technological Development Zone [2] - The main business areas include in vitro diagnostic reagents (biochemical, immunological, molecular), diagnostic instruments, and biochemical raw materials. The revenue composition is as follows: in vitro diagnostic reagents 67.84%, diagnostic instruments 14.17%, other (property leasing/management, etc.) 13.21%, and biochemical raw materials 4.78% [2] Financial Performance - For the first half of 2025, Lidman reported operating revenue of 160 million yuan, a year-on-year decrease of 14.80%. The net profit attributable to the parent company was -4.25 million yuan, a year-on-year decrease of 800.43% [2] - Since its A-share listing, Lidman has distributed a total of 143 million yuan in dividends, with 5.44 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Lidman was 35,300, a slight decrease of 0.06% from the previous period. The average circulating shares per person increased by 0.06% to 15,383 shares [2] - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund (004685) is the eighth largest with 2.41 million shares, an increase of 424,900 shares from the previous period. Hua Xia Zhong Zheng 500 Index Enhanced A (007994) is the ninth largest with 2.20 million shares, marking a new entry [3] Market Activity - On September 19, Lidman's stock price fell by 2.04%, trading at 7.68 yuan per share with a total transaction volume of 79.53 million yuan and a turnover rate of 1.89%. The total market capitalization is 4.178 billion yuan [1] - In terms of capital flow, there was a net outflow of 4.35 million yuan from main funds, with large orders accounting for 15.31% of purchases and 18.34% of sales [1]

Group 1: Company Research - Jiasai Fund recently conducted research on five listed companies, including Shiji Information, which signed a significant operational contract with Amadeus to create a comprehensive technology platform for travel [1] - Juhua Materials plans to invest 68 billion KRW in acquiring SK Enpulse's blank mask business, with a direct or indirect investment ratio of no less than 95% [2] - China Nuclear Power has received over 2.8 billion CNY in new energy subsidies as of the end of August, expecting a total of about 4 billion CNY for the year [3] - XCMG Machinery's stock incentive plan includes ROE, net profit, and cash flow from operating activities as assessment indicators, aiming for over 40 billion CNY in revenue from the mining machinery sector by 2030 [4] - Lide Man's revenue is expected to decline by 14.80% in the first half of 2025 due to intensified industry competition and the implementation of centralized procurement policies [5] Group 2: Industry Insights - The collaboration between Shiji Information and Amadeus is expected to enhance customer confidence and benefit the annual recurring revenue (ARR) growth in 2026 [1] - Juhua Materials aims to address domestic "bottleneck" issues in core raw materials through its acquisition strategy [2] - China Nuclear Power is focusing on digital transformation and smart operations while maintaining a dividend payout ratio of over 35% despite capital pressures from 19 ongoing projects [3] - XCMG Machinery anticipates continued growth in overseas market exports, with domestic sales benefiting from policy incentives and the renewal cycle [4] - Lide Man is pursuing a cash acquisition of up to 70% of Xiansheng Xiangrui to expand its tuberculosis diagnosis and innovative vaccine business [5]